<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92966</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Primenenie malobelkovoy diety u bol'nykh s khronicheskoy pochechnoy nedostatochnost'yu</article-title><trans-title-group xml:lang="ru"><trans-title>Применение малобелковой диеты у больных с хронической почечной недостаточностью</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ermolenko</surname><given-names>V. M</given-names></name><name xml:lang="ru"><surname>Ермоленко</surname><given-names>В. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Российская медицинская академия последипломного образования, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2009-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2009</year></pub-date><volume>11</volume><issue>7</issue><issue-title xml:lang="en">VOL 11, NO7 (2009)</issue-title><issue-title xml:lang="ru">ТОМ 11, №7 (2009)</issue-title><fpage>14</fpage><lpage>16</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2009, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2009, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/92966">https://consilium.orscience.ru/2075-1753/article/view/92966</self-uri><abstract xml:lang="ru"><p>Малобелковая диета (МБД) вошла в стандартную практику терапевтов и нефрологов более 130 лет назад [1]. Основными причинами применения МБД у пациентов, страдающих хронической почечной недостаточностью (ХПН), являются: 1) уменьшение выраженности уремических симптомов и метаболических нарушений, связанных с почечной недостаточностью (ПН); 2) замедление потери остаточной функции почек. Хотя надлежащее применение МБД улучшает метаболизм без риска нутритивных нарушений, специально разработанные диеты во многих нефрологических отделениях не всегда назначаются систематически [4]. Во многих исследованиях, включая несколько метаанализов, показано, что этот достаточно несложный метод воздействия может замедлить прогрессирование почечной недостаточности и оказывает другие положительные эффекты [2, 3, 5–8]. МБД относится к рекомендациям высокой степени доказательности для пациентов с ХПН как диабетической, так и недиабетической этиологии. Основными целями МБД являются коррекция метаболических нарушений и продление додиализного периода. Додиализный период крайне важен для жизни пациента [9, 10], и с экономической точки зрения целесообразно обязательное назначение МБД для его пролонгации в связи с увеличивающейся стоимостью диализной терапии и большего риска смерти пациентов после начала диализа. Начало диализа при применении МБД может быть отсрочено в среднем больше чем на 1 год [9–11]. Имеется много доказательств того, что при назначении МБД отмечаются уменьшение выраженности симптомов уремического синдрома, снижение выраженности гиперпаратиреоза, повышение чувствительности к инсулину, уменьшение частоты метаболического ацидоза, снижение протеинурии, улучшение контроля артериальной гипертензии, а также субъективного самочувствия пациента.</p></abstract></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Walser M, Mitch W.E., Maroni B.J., Kopple J.D. Should protein be restricted in predialysis patients? Kidney Int 1999; 55: 771–7.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Klahr S, Levey A.S., Beck G.L. et al. The effects of dietary protein restriction and blood -pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl Med 1994; 330: 877–84.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Mitch W.E. Dietary therapy in uremia: the impact on nutrition and progressive renal failure. Kidney Int 2000; 57 (Suppl. 75): S38–43.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601–8.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Fouque D, Laville M, Boissel J.P. et al. Controlled low protein diets in chronic renal insufficiency: meta - analysis. Br Med 1992; 304: 216–20.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Pedrini M.T., Levey A.S., Lau J et al. The effect of dietary protein restriction on the progression of diabetic and non - diabetic renal diseases: a meta - analysis. Ann Intern Med 1996; 124: 627–32.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kasiske B.L., Lakatua J.D.A., Ma J.Z., Louis T.A. A meta - analysis of the effects of dietary protein restriction on the rate of decline of renal function. Am J Kidney Dis 1998; 31: 954–61.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fouque D, Wang P, Laville M, Boissel J.P. Low protein diets delay end - stage renal disease in non diabetic adults with chronic renal failure. Nephrol Dial Transpl 2000; 15: 1986–92.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Walser M, Hill S. Can renal replacement be deferred by a supplemented very - low diet? J Am Soc Nephrol 1999; 10: 110–6.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Aparicio M, Chauvenau P, De Precigout V et al. Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet. J Am Soc Nephrol 2000; 11: 708–16.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mitch W.E. Are supplements of ketoacids and amino acids useful in treating patients with chronic renal failure. Wien Klin Wochenschr 2000; 112: 863–4.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Mitch W.E., Maronu B.J. Nutritional consideration in the treatment of patients with chronic uremia. Miner Electrolyte Metab 1998; 24: 285–9.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Masud T, Young W.R., Chapman T, Maroni B. Adaptive response to very low protein diets: the first comparison of ketoacids to essential amino acids. Kidney Int 1994; 45: 1182–92.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Walser M, Hill S, Ward L. Progression of chronic renal failure on substituting a ketoacid supplement for an amino acid supplement. J Am Soc Nephrol 1992; 2: 1178–85.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Teschan P.E., Beck G.E., Dwyer J.T. et al. Effect of a keto acid amino acid – supplemented very low protein diet on the progression of advanced renal disease: a reanalysis of the MDRD feasibility study. Clin Nephrol 1998; 50: 273–83.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Walser M, Hill S.B., Ward L, Magder L. A crossover comparison of progression of chronic renal failure: ketoacids versus amino acids. Kidney Int 1993; 43: 933–9.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Mitch W.E., Clark A.S. Specificity of the effect of leucine and its metabolites on protein degradation in the skeletal muscle. Biochem J 1984; 222: 579–89.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Frьhling P.T., Kokot F, Schmicker R et al. Influence of keto acids on serum parathyroid hormone levels in patients with chronic renal failure. Clin Nephrol 1983; 20: 212–5.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Teplan V, Schck O, Horckov M et al. Effect of keto acid - amino acid supplement on the metabolism and renal elimination of branched - chain amino acids in patients with chronic renal insufficiency on a low protein diet. Wien Klin Wochenschr 2000; 112: 876–81.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Teplan V, Schck O, Vortuba M et al. Metabolic effect of keto acid – amino acid supplementation in patients with chronic renal insufficiency receiving a low - protein diet and recombinant human erythropoietin – A randomized controlled trial. Wien Klin Wochenschr 2001; 113: 661–9.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Aparicio M, Gin H, Potaux L et al. Effect of a keto acid diet on glucose tolerance and tissue insulin sensitivity. Kidney Int 1998 ; Suppl. 27: 231–5.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Bernard S, Fouque D, Laville M, Zech P. Effect of low - protein diet supplemented with ketoacids on plasma lipids in adult chronic renal failure. Miner Electrolyte Metab 1996; 22: 143–6.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Peuchant E, Delmas-Beauvieux M.C., Dubourg L et al. Antioxidant effects of a supplemented very low protein diet in chronic renal failure. Free Radical Biol Med 1997; 22: 313–20.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Hirschberg R, Cohen A.H., Kopple J.D. Effects of keto acid supplements on renal function and histology in azotemic rats fed high - protein diets. Am J Nephrol 1998; 8: 50–6.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Zakar G for the Hungarian Ketosteril Cohort Study. The effect of a keto acid supplement on the course of chronic renal failure and nutritional parameters in predialysis patients and patients on regular hemodialysis therapy: The Hungarian Ketosteril Cohort Study. Wien Klin Wochenschr 2001; 113: 688–94.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Druml W. Supplements of ketoacids in patients with chronic renal falure – more than modulators of nitrogen economy. Wiener Klinische Wochenschrift 2001; 113/17–18: 638–40.</mixed-citation></ref></ref-list></back></article>
